Sign In
Buy FLXN
$25.10
-0.0069 (-0.0275%)
At Close: Jun 22, 2026
It's Time To Buy Flexion Therapeutics As Revenue Is Expected To Grow
05:04pm, Tuesday, 04'th May 2021
Last month, management guided Zilretta revenue to grow 50% to $120-130 million. Huge runway with under 5% market penetration into osteoarthritis knee pain indication. Despite growing revenue nearly 20
BURLINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will present preliminary data from a Phase 1 single ascending dose (SAD) trial of FX201 at the 2021 Ameri
Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021
04:01pm, Tuesday, 13'th Apr 2021
BURLINGTON, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net
Abercrombie, Pfizer, Teva and More of Wednesday Afternoon Analyst Calls
11:45am, Wednesday, 07'th Apr 2021
With the trading day approaching halfway over, the broad markets were trading marginally positive.
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 02'nd Apr 2021
BURLINGTON, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 60,880 restricted stock unit
Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2020 Results - Earnings Call Transcript
08:47pm, Wednesday, 10'th Mar 2021
Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2020 Results - Earnings Call Transcript
Flexion Therapeutics: Q4 Earnings Insights
04:22pm, Wednesday, 10'th Mar 2021
Shares of Flexion Therapeutics (NASDAQ:FLXN) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 57.47% over the past year to ($0.37), whic
Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results
04:01pm, Wednesday, 10'th Mar 2021
BURLINGTON, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter and the full year ended D
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 05'th Mar 2021
BURLINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of 14,565 restricted stock unit
Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021
04:30pm, Wednesday, 03'rd Mar 2021
BURLINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the clo
Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery
12:58pm, Monday, 01'st Mar 2021
The FDA signed off Flexion Therapeutics Inc's (NASDAQ: FLXN) Phase 1b proof of concept trial evaluating FX301 administered as a popliteal fossa block (a commonly used nerve block in the foot and a
BURLINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) ap
Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference
04:30pm, Monday, 22'nd Feb 2021
BURLINGTON, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an
- Sheryl Swoopes, WNBA Legend, Basketball Hall of Famer and ZILRETTA Patient, Tips Off Educational Campaign About ZILRETTA and Osteoarthritis Knee Pain - Sheryl Swoopes, WNBA Legend, Basketball Hall
Flexion Therapeutics: Fighting Through COVID-19 Headwinds
03:00pm, Sunday, 17'th Jan 2021
Flexion Therapeutics recently reported their Q4 and full-year 2020 results that revealed record sales for ZILRETTA and encouraging commercial metrics. Despite the COVID-19 headwinds, the company conti
